Navigation Links
New Treatment Against Osteoarthritis: Orthokine Therapy Highly Effective Against Knee Arthritis After Two Years
Date:2/23/2009

DÿSSELDORF, Germany, February 23 /PRNewswire/ -- An international team of researchers has evaluated the effectiveness of Orthokine therapy for osteoarthritis of the knee, and the results have been published in the February edition of the specialist journal "Osteoarthritis and Cartilage". The researchers followed 376 patients to determine the effectiveness of various osteoarthritis treatments. After six months as well as after two years, patients who received Orthokine therapy experienced significantly less pain and more improved joint function than those who received hyaluronic acid or a placebo. Orthokine therapy is a biotechnology-based method in which proteins that inhibit inflammation are obtained from the patient's own blood and injected into the affected joint.

"In this study and for several thousand patients whom we have treated, Orthokine has proven an extraordinarily safe and effective way of treating osteoarthritis of the knee. I am delighted that distinguished experts have now confirmed these findings," said Dr. Peter Wehling, CEO of ORTHOGEN AG, in Düsseldorf on February 21. "We are now planning to distribute the IP-protected Orthokine technology world- wide. Orthokine is already being distributed in various EU countries through ORTHOGEN or other distributors."

Orthokine is the first scientifically proven, placebo-controlled autologous therapy in the orthopaedic field.

This kind of therapy was recently discussed in The New York Times. Two of the Pittsburgh Steelers' biggest stars, Hines Ward and Troy Polamalu, used their own blood cells in an innovative injury treatment before winning the Super Bowl.

    To find out more:
   http://www.oarsijournal.com/
   http://www.oarsi.org

    For more information please contact:
    Orthogen AG
    Press and Public Relations
    Elena Kawadopulos
    Graf-Adolf-Str. 43
    40210 Düsseldorf
    Tel.: +49-211-3670076
    Fax: +49-211-3670010
    Mobile: +49-177-588-3442
    E-Mail: elena.kawadopulos@orthogen.com
   http://www.orthogen.com


'/>"/>
SOURCE Orthogen AG
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Breast Cancer Patients May Have a New Treatment Option When Cancer Spreads
2. American Heart Association EMS Survey Uncovers Deficiencies in Response, Treatment and Transfer of Patients With Most Deadly Heart Attacks
3. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
4. Study Suggests New Treatment Approach May be Needed for Management of Depression in Some People With Bipolar Disorder
5. Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments
6. Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
7. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
8. Positive Data From Lung Study May Lead to First FDA Approved Treatment for Pulmonary Fibrosis
9. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
10. Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis
11. Medgenics Announces Positive Data From Phase I/II Clinical Trial of EPODURE Treatment of Anemia in Chronic Kidney Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
(Date:9/28/2017)... -- Cohen Veterans Bioscience and Early Signal Foundation announce ... home sensors for real-time monitoring of patients with trauma-related ... organization focused on disruptive health solutions for rare disorders ... to record and integrate behavioral, cognitive, physiological and contextual ... ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
Breaking Medicine Technology:
(Date:10/13/2017)... Calif. (PRWEB) , ... October 13, 2017 , ... Many ... dementia. However, many long-term care insurance companies have a waiver for care if the ... 90-day elimination period, when the family pays for care, is often waived, so the ...
(Date:10/13/2017)... ... 13, 2017 , ... Talented host, actor Rob Lowe, is ... a new episode of "Success Files," which is an award-winning educational program broadcasted ... each subject in-depth with passion and integrity. , Sciatica occurs when the sciatic ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... AccentCare, a leader in post-acute health care, have expanded their existing home health ... Home Health. , AccentCare has been operating a joint venture home health company ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & Wellness ... Moonlight to raise money for the American Heart Association Heart Walk. Teams of up ... work together to keep their treadmills moving for 5 hours. Treadmills will start at ...
Breaking Medicine News(10 mins):